Orthocell Achieves First Remplir Sales in Thailand
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Orthocell Ltd has announced its first commercial sales of Remplir in Thailand, marking a significant milestone in its growth strategy in Asia and globally. The sales follow Thai FDA approval and the appointment of MediTime as the exclusive distributor, which will facilitate market entry through established relationships with hospitals. Orthocell is actively coordinating the product launch and training with MediTime to engage prospective customers and build surgeon awareness. The company remains well funded, supporting its ongoing commercial expansion efforts.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Orthocell
- Cleansing Notice
- Application for quotation of securities - OCC
- Date of AGM & Closing Date for Director Nominations
- Appendix 4G
- Corporate Governance Statement
Later from Orthocell
- Change of Auditor
- Letter to Shareholders, Notice of AGM & Proxy Form
- Remplir Shows Excellent Early Prostatectomy Results
- Orthocell Investor Webinar Details
- Quarterly Activity Report & Appendix 4C
Follow Orthocell into a list and get an email when it puts out news.
Follow Orthocell